Association of Tetanus-Diphtheria Vaccination during Pregnancy with Preeclampsia  

作　　者：Kubilay Canga Pervin Karli Ayse Zehra Ozdemir Mesut Onal Idris Kocak 

机构地区：[1]Department of Obstetrics and Gynecology,Ondokuz Mayis University Research Hospital,Samsun,Turkey [2]Department of Obstetrics and Gynecology,Amasya University Research Hospital,Amasya,Turkey

出　　处：《Open Journal of Obstetrics and Gynecology》2018年第12期1130-1139,共10页妇产科期刊（英文）

摘　　要：Introduction: The tetanus-diphtheria vaccine administered during pregnancy is used as a toxoid vaccine with an intact antigen structure. In this study, we investigated the association of tetanus-diphtheria vaccination (TDV) during pregnancy with adverse maternal and neonatal outcomes and particularly preeclampsia that may occur during pregnancy. Materials and Methods: From the patients who presented to our clinic between 01.01.2016 and 31.12.2016 and underwent a cesarean section, a total of 435 patients, 327 who received TDV and 108 who did not receive TDV, were included in the study. The groups were compared with respect to their demographic characteristics. The patient data on the gestational week, birth weight, normal newborn, preeclampsia, small for gestational age (SGA), early membrane rupture, preterm labor, diabetic mother’s baby, prematurity, temporary neonatal tachypnea, newborn’s need for intensive care, and neonatal mortality were recorded. Results: While 14.7% of the women who had been administered TDV had preeclampsia diagnosis during their pregnancy, 12% of those who had not been vaccinated were diagnosed with preeclampsia. This showed no significant correlation between having been vaccinated during pregnancy and preeclampsia (p = 0.474). The other outcomes we had specified had also no statistically significant correlations with vaccination during pregnancy. Having been vaccinated during pregnancy was found correlated only with the place of residence and nulliparity (p = 0.004 and p = 0.002, respectively). Conclusion: No correlation was found in the study between TDV during pregnancy and preeclampsia. According to the data obtained from this study, vaccination was found to have no negative effect on preeclampsia or the other outcomes.Introduction: The tetanus-diphtheria vaccine administered during pregnancy is used as a toxoid vaccine with an intact antigen structure. In this study, we investigated the association of tetanus-diphtheria vaccination (TDV) during pregnancy with adverse maternal and neonatal outcomes and particularly preeclampsia that may occur during pregnancy. Materials and Methods: From the patients who presented to our clinic between 01.01.2016 and 31.12.2016 and underwent a cesarean section, a total of 435 patients, 327 who received TDV and 108 who did not receive TDV, were included in the study. The groups were compared with respect to their demographic characteristics. The patient data on the gestational week, birth weight, normal newborn, preeclampsia, small for gestational age (SGA), early membrane rupture, preterm labor, diabetic mother’s baby, prematurity, temporary neonatal tachypnea, newborn’s need for intensive care, and neonatal mortality were recorded. Results: While 14.7% of the women who had been administered TDV had preeclampsia diagnosis during their pregnancy, 12% of those who had not been vaccinated were diagnosed with preeclampsia. This showed no significant correlation between having been vaccinated during pregnancy and preeclampsia (p = 0.474). The other outcomes we had specified had also no statistically significant correlations with vaccination during pregnancy. Having been vaccinated during pregnancy was found correlated only with the place of residence and nulliparity (p = 0.004 and p = 0.002, respectively). Conclusion: No correlation was found in the study between TDV during pregnancy and preeclampsia. According to the data obtained from this study, vaccination was found to have no negative effect on preeclampsia or the other outcomes.

关 键 词：PREECLAMPSIA Tetanus-Diphtheria Vaccination Vaccination in Pregnancy VACCINATION PREGNANCY 

分 类 号：R73[医药卫生—肿瘤]